Please see below for a list of search results.
Issued March 2010 Umbilical cord blood (cord blood) is collected at the time of birth and stored so that it may be available for potential future treatment of the child or another person.
The Human Tissue Authority (HTA) welcomes the publication of the report from the Regenerative Medicine Expert Group, “Building on our own potential: a UK pathway for regenerative medicine”.
The HTA was asked to share a letter written to the University of Bristol regarding a process taking place at the university in 2008, as part of a process to create an artificial trachea for transplant
Umbilical cord blood may be collected at the time of birth and stored, so that it is available for potential future treatment of the child or another person.
The aim of regulating human embryonic stem cells is to ensure that the highest standards are met from their derivation in the laboratory through to their clinical application.
The Designated Individual (DI) at the licensed establishment is responsible for ensuring suitable practices take place under the authority of the Human Tissue Authority (HTA) licence.
The HTA is responsible for assessing all donations of bone marrow or PBSC (these are cells found in the bloodstream which are able to develop into all of the different cell types in blood) from adults who lack capacity to consent and children who lack competence to consent.
The Human Tissue Act 2004 (HT Act) provides the legal framework for bone marrow and peripheral blood stem cell (PBSC) donation in England, Wales and Northern Ireland.
The Regulatory Advice Service for Regenerative Medicine (the Advice Service) is a ‘One Stop Shop’ for research and development professionals across academia, industry, and the NHS. It offers a single point of access to free, clear, expert responses to queries about the regulation of regenerative...